Last reviewed · How we verify
NCT02485652
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
Phase 2 trial testing HM61713 in Non Small Cell Lung Cancer in 162 participants. Terminated before completion.
8 December 2020
Quick facts
| Lead sponsor | Hanmi Pharmaceutical Company Limited |
|---|---|
| Phase | Phase 2 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 162 |
| Start date | 31 August 2015 |
| Primary completion | 8 December 2020 |
| Estimated completion | 8 December 2020 |
| Sites | 72 locations across Italy, Malaysia, Taiwan, Germany, South Korea, Philippines, Canada, Australia |
Drugs / interventions tested
- HM61713 — full drug profile →
Conditions studied
- Non Small Cell Lung Cancer — all drugs for Non Small Cell Lung Cancer →
Sponsor
Hanmi Pharmaceutical Company Limited — full company profile →
Who can join
20 and older, any sex, with Non Small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy, safety and pharmacokinetics of HM61713 in patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives.
Zhong L, Li Y, Xiong L, Wang W, et al · · 2021 · cited 1003× · PMID 34054126 · DOI 10.1038/s41392-021-00572-w -
Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors.
Du X, Yang B, An Q, Assaraf YG, et al · · 2021 · cited 101× · PMID 34557754 · DOI 10.1016/j.xinn.2021.100103 -
The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).
Cheng Z, Cui H, Wang Y, Yang J, et al · · 2024 · cited 37× · PMID 38063215 · DOI 10.3892/or.2023.8675 -
Predictive and Prognostic Biomarkers for Lung Cancer Bone Metastasis and Their Therapeutic Value.
Chai X, Yinwang E, Wang Z, Wang Z, et al · · 2021 · cited 36× · PMID 34722241 · DOI 10.3389/fonc.2021.692788 -
<i>EGFR</i> T790M: revealing the secrets of a gatekeeper.
Ko B, Paucar D, Halmos B. · · 2017 · cited 36× · PMID 29070957 · DOI 10.2147/lctt.s117944 -
Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors.
Liao BC, Lin CC, Lee JH, Yang JC. · · 2016 · cited 36× · PMID 27912760 · DOI 10.1186/s12929-016-0305-9 -
Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer.
Chu CY, Choi J, Eaby-Sandy B, Langer CJ, et al · · 2018 · cited 35× · PMID 29650685 · DOI 10.1634/theoncologist.2017-0582 -
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study.
Park K, Jӓnne PA, Kim DW, Han JY, et al · · 2021 · cited 23× · PMID 33434335 · DOI 10.1002/cncr.33385
Verify or expand the search:
- PubMed search for NCT02485652
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Non Small Cell Lung Cancer
Currently open trials in the same condition.
- NCT06951646 — ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immuno · Phase 2 · recruiting
- NCT07503808 — A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types · Phase 1 · recruiting
- NCT07269782 — A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCL · Phase 2 · recruiting
- NCT07306624 — Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer · Phase 2 · recruiting
- NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
Other Hanmi Pharmaceutical Company Limited trials
Trials by the same sponsor.
- NCT07297693 — A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT06595004 — A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients · Phase 3 · completed
- NCT06518122 — A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers · Phase 1 · completed
- NCT06481098 — A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects. · Phase 1 · completed
- NCT06357910 — A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy V · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02485652 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hanmi Pharmaceutical Company Limited
- Last refreshed: 22 January 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02485652.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing